GWM
PTCT icon

Gilpin Wealth Management’s PTC Therapeutics PTCT Stock Holding History

Gilpin Wealth Management’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$898 Sell
11
-3
-21% -$217 ﹤0.01% 524
2026
Q1 		$954 Buy
14
+8
+133% +$567 ﹤0.01% 487
2025
Q4 		$456 Buy
+6
New +$436 ﹤0.01% 463

Other funds holding PTCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Gilpin Wealth Management's PTCT Position: Q2 2026 in Review

Gilpin Wealth Management reduced its PTC Therapeutics (PTCT) stake by 21% in Q2 2026, selling an estimated $217 and leaving 11 shares worth $898. The position accounts for ﹤0.01% of the portfolio, ranked #524.

Gilpin Wealth Management first reported a position in PTCT in Q4 2025 and has held it in 3 quarters since. The position peaked at $954 in Q1 2026. 381 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

  • Gilpin Wealth Management held 11 shares of PTC Therapeutics worth $898 as of Q2 2026.
  • Gilpin Wealth Management sold 3 PTC Therapeutics shares in Q2 2026, an estimated $217.
  • PTC Therapeutics made up ﹤0.01% of Gilpin Wealth Management's portfolio in Q2 2026, its #524 holding.
  • Gilpin Wealth Management first reported a position in PTC Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Gilpin Wealth Management's PTC Therapeutics position peaked at $954 in Q1 2026.
  • 381 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Gilpin Wealth Management's 13F filing for Q2 2026, filed 24 Jul 2026.